Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma

Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using ipilimumab and nivolumab has recently been approved as a frontline therapy, but this led to only a small improveme...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer research communications Jg. 4; H. 1; S. 18 - 27
Hauptverfasser:	Badhai, Jitendra, Landman, Nick, Pandey, Gaurav Kumar, Song, Ji-Ying, Hulsman, Danielle, Krijgsman, Oscar, Chandrasekaran, Gayathri, Berns, Anton, van Lohuizen, Maarten
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States American Association for Cancer Research 03.01.2024
Schlagworte:	Animals Biomarkers Enhancer of Zeste Homolog 2 Protein - genetics Humans Lung Cancer Lung Neoplasms - drug therapy Melanoma - drug therapy Mesothelioma - drug therapy Mesothelioma, Malignant Mice Preclinical Models Small Molecule Agents Translational Research Tumor Suppressor Proteins - genetics Ubiquitin Thiolesterase - genetics
ISSN:	2767-9764, 2767-9764
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!